P reventing and/or treating constipation in patients is a common concern for clinicians. Up to 43% of inpatients experience constipation within the first 3 days of hospital admission. 1 Constipation increases discomfort and may lead to abdominal cramping and straining on defecation that ultimately affect quality of life. 2 Docusate is an over-the-counter medication classified as a stool softener that is primarily used to prevent constipation and is commonly prescribed in the community and hospital settings. Docusate acts as an emollient and surfactant to emulsify stool and is marketed to aid in the passage of hardened stool. 3 The efficacy of docusate in the prevention of constipation has been questioned in several studies and review articles, [4] [5] [6] including a systematic review 7 that concluded that docusate appears to be no more effective than placebo. Docusate did not lessen symptoms associated with constipation (ie, abdominal cramps) or affect the perceptions associated with completeness of or difficulties with stool evacuation. Although the quality of studies is generally poor and the patients studied were not generalizable to all patients with constipation, it can be concluded that docusate is not beneficial in the prevention of constipation. In general, laxatives (and especially docusate) are inexpensive to purchase. However, because of their volume of administration, the systemwide indirect costs are substantial, involving pharmacy procurement and distribution, nursing administration, and patient pill burden. Lee et al 8 found that, in their facility, docusate accounted for 64% of total laxative administration, and 50% of patients were discharged with prescriptions for the medication, extending pill burden and costs into the community. Continued administration of docusate despite its documented lack of efficacy is driven by several factors, including inexpensive individual procurement costs, historical and longstanding administration, apathy toward intervening on a perceived innocuous substance, ongoing inclusion in textbooks and guidelines, and potential complexity in changing practice. Initial discussions with stakeholders in our organization indicated the need for a straightforward approach that would not administratively burden frontline staff. As a result, a phased approach to reducing docusate administration was used, beginning with broad education.
Alberta Health Services (AHS) Pharmacy Services regularly publishes Drugs & Therapeutics Backgrounders, which are academic detailing tools that briefly summarize evidence about the safety, efficacy, and sustainability of medications. Pharmacists use these to supplement therapeutic conversations with prescribers. In December 2014, Stool Softeners: WHY Are They Still Used? 9 was published. It describes the evidence for lack of efficacy of docusate and includes a clear call to action that docusate use can be discontinued safely and, unless clinically necessary, not be replaced with another medication. Pharmacists are not directed to use the backgrounder in a specific manner but encouraged to use the information in interactions with prescribers, nurses, and patients to avoid or discontinue the use of docusate. The backgrounder was supported by 2 interactive webinars in which the author provided context and answered any questions from the audience. We hypothesized that a straightforward, multimodal communication process with messaging and a call to action would reduce the amount of docusate dispensed and would not result in subsequent increases in the administration of comparable laxative medications.
Methods
We conducted an uncontrolled pre-post study in AHS. Alberta is a Canadian province with 4.2 million individuals, and all Albertans are provided publicly funded health coverage through the Canada Health Act.
10 Alberta Health Services and its affiliated organizations are responsible for health care delivery at 106 acute care hospitals, 5 psychiatric facilities, and 24 000 continuing care beds, which were included in this study. 11 We used Alberta Innovates' Project Ethics Community Consensus Initiative ethics guidelines for quality improvement and evaluation projects to guide this study. 12 The Project Ethics Community Consensus Initiative Ethics Screening Tool assessed the ethical risk of this quality improvement initiative to be minimal risk, and review by a research ethics board was not deemed to be necessary. 13 The primary objective was to determine the association of the backgrounder with the administration of docusate in inpatients and nursing home residents for a period of 18 months after the intervention. As a secondary objective, we assessed whether there was an association of the change in docusate administration with the administration of comparable laxative medications with mechanisms of action that improve the pliability of stool. Stimulant laxatives (eg, senna, bisacodyl) were excluded because their mechanism of action differs greatly from that of the study medications. Meaning A concise message, with a clear call to action, can significantly decrease the clinician administration of a medication that has limited efficacy.
Quantities of study medications (docusate, polyethylene glycol 3350, lactulose, magnesium hydroxide, and psyllium) dispensed to inpatients and nursing home residents each month were obtained from pharmacy dispensing systems used in AHS (MediTech, Medical Information Technology Inc, BDM, BDM IT Solutions Inc, Centricity, and HE Healthcare) from June 1, 2014, through May 31, 2016. These data were converted to defined daily doses (DDDs) and standardized for bed use by dividing by 1000 inpatient-days (PDs) ( Table 1) .
14 Docusate expenditures were obtained from AHS Pharmacy Services Procurement and Inventory. Changes in DDDs per 1000 PDs for docusate and the composite of comparable laxatives during the baseline period were compared by interrupted time series analysis to rates at 3, 6, 12, and 18 months after the intervention.
16 SPSS statistical software, version 19 (IBM Inc) was used for autoregressive integrated moving average analysis and applied interrupted time series techniques described by the Cochrane Effective Practice and Organisation of Care Group. 17 Autoregressive integrated moving average analysis was used to calculate P values, with a 1-sided significance level of P < .05.
Results
In the 6 months before backgrounder dissemination, the administration of docusate was stable at 474 DDDs/1000 PDs and the administration of the composite of comparable laxatives was stable at 627 DDDs/1000 PDs (Figure and (Table 2) . Total docusate DDDs dispensed decreased by approximately 50 000 per month from the predissemination period to the 18 months after dissemination. The composite of comparable laxative medications dipensed did not statistically significantly change from the baseline (627 DDDs/ 1000 PDs) to the postintervention period, with 95% CIs at all observation points not contained below unity (3 months: 646 DDDs/ 1000 PDs; 95% CI, 483-639 DDDs/1000 PDs; P = .06; 6 months: 656 DDDs/1000 PDs; 95% CI, 460-645 DDDs/1000 PDs; P = .07; 12 months: 710 DDDs/1000 PDs; 95% CI, 371-671 DDDs/1000 PDs; P = .11; 18 months: 702 DDDs/1000 PDs; 95% CI, 295-694 DDDs/ 1000 PDs; P = .13) ( Table 2 ).
Discussion
Administration of docusate for constipation prevention is not supported by published evidence, although it remains a considerable driver of health care resource use. The blended communication method that we used conveyed the backgrounder messages effectively and was associated with a decrease in docusate administration by more than half in the 18 months after dissemination of the backgrounder and the webinar sessions.
Observations at 3 and 6 months exceeded the threshold established for downward trends greater than in the baseline period. Although the 95% CIs at 12 and 18 months were not contained below unity, this would indicate a flattening of the rate of decrease. Slowing of the rate of decrease is expected during an extended follow-up period, when no further reminders are provided.
The composite of comparable laxative medications did not change correspondingly, with 95% CIs crossing zero at all study intervals. This finding indicates that docusate was not being replaced with more expensive alternatives.
Pharmacoeconomic analysis was not an objective of this study but warrants discussion. Annual docusate purchases were approximately $100 000 before the intervention and $30 000 at the conclusion, representing a small fraction of AHS's total drug budget. Lee et al 8 used an estimate of 45 seconds as the time required for a nurse to administer a dose of medication. At the conclusion of the study period, approximately 50 000 fewer docusate DDDs (75 000 × 100-mg doses) were dispensed across the organization per month than at the beginning of the study, which would equal approximately 940 hours of nursing time. We acknowledge that shifting workload in this manner does not result in monetary savings for the organization, but it cumulatively improves time efficiency, which benefits patient care.
Limitations
Because of the limitation of the current pharmacy dispensing systems, we could not account for wasted and expired medication or administration for other indications. We also could not rule out the effect of external influences on pharmacists and prescriber's perceptions about docusate administration.
